Bettan-Renaud L, de Vathaire F, Bénard J, Morardet N, Pauzie N, Bayet S, Hartmann O, Parmentier C
Laboratoire de Pharmacologie Clinique et Moléculaire, Institut Gustave Roussy, Villejuif, France.
Br J Cancer. 1989 Oct;60(4):529-32. doi: 10.1038/bjc.1989.307.
Cisplatinum may prove to be a valuable agent for the elimination of diseased cells in the bone marrow of patients with neuroblastoma. In this study, we measured the efficacy of cisplatinum on human neuroblastoma cell lines and on normal human bone marrow progenitors, GM-CFC and CFU-F. Data indicate that the therapeutic index of cisplatinum is high. We set up an experimental model consisting of a mixture of human bone marrow and human neuroblastoma cells in order to confirm these preliminary results in purging conditions. Results indicate that cisplatinum exhibits a high and specific tumoricidal property and appears to be valid in bone marrow purging.
顺铂可能被证明是一种用于消除神经母细胞瘤患者骨髓中病变细胞的有价值药物。在本研究中,我们测定了顺铂对人神经母细胞瘤细胞系以及对正常人骨髓祖细胞GM-CFC和CFU-F的疗效。数据表明顺铂的治疗指数很高。我们建立了一个由人骨髓和人神经母细胞瘤细胞混合物组成的实验模型,以便在净化条件下证实这些初步结果。结果表明顺铂具有高度特异性的杀肿瘤特性,并且在骨髓净化中似乎是有效的。